ResearchRSS2 days ago
Scientists found that a gene called RUNX1 might help doctors predict when patients with pulmonary arterial hypertension (PAH) — a serious lung disease that makes it hard to pump blood — could develop heart problems. When the right side of the heart weakens in PAH patients, it becomes very dangerous. This discovery could help doctors catch and treat these heart problems earlier.
WHY IT MATTERSIf RUNX1 becomes a validated biomarker, PAH patients could receive earlier interventions to prevent right heart failure, potentially improving survival and quality of life before irreversible damage occurs.
NewsRSS2 days ago
This article is a quiz that tests what you know about riociguat, a medication used to treat pulmonary arterial hypertension (PAH). PAH is a rare condition where blood vessels in the lungs become narrowed, making it harder for the heart to pump blood through them. The quiz helps patients and caregivers learn more about how this treatment works.
WHY IT MATTERSUnderstanding how riociguat works and its role in PAH treatment can help patients make informed decisions about their care and have more meaningful conversations with their doctors about their treatment options.
Clinical trialRSS2 days ago
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
WHY IT MATTERSIf you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
NewsRSS2 days ago
Orenitram is a pill form of a medicine called treprostinil that helps people with pulmonary arterial hypertension (a serious lung condition where blood vessels in the lungs become too narrow). You take it by mouth 2-3 times a day with food. This medicine helps patients exercise better and slows down how fast their disease gets worse.
WHY IT MATTERSThis oral option gives PAH patients an alternative to injected or inhaled treprostinil, making treatment more convenient for daily management.
ResearchRSS2 days ago
Researchers found that data from smartphones and wearable devices, collected over several years through a health app, can help doctors identify people with a rare lung disease called idiopathic pulmonary arterial hypertension (IPAH) earlier than before. The study used information like heart rate and activity levels from the My Heart Counts app to spot differences between people with IPAH and healthy people. This discovery could lead to faster diagnosis of this serious condition.
WHY IT MATTERSEarlier detection of IPAH could allow patients to start treatment sooner, potentially slowing disease progression and improving outcomes for this condition that currently has no cure.